Biosimilars Could Cut Spending for Biologic Therapy in the US
Increased market growth of biosimilars that are similar to brand-name biologic agents has the potential to reduce spending on prescription drugs
Immune Disorders
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Novel Immunomodulator Gets Orphan Drug Status for Sarcoidosis
Results from a phase 1/2 showed that ATYR1923 was safe and well tolerated.
Orencia Approved for Prevention of Acute Graft Versus Host Disease
The approval was based on data from the placebo-controlled phase 2 GVHD-1 trial and real world evidence from a registry trial.
Cutaquig Approved for Pediatric Patients With Primary Humoral Immunodeficiency
Cutaquig is a ready-to-use immune globulin solution for subcutaneous infusion.
October 2021: 5 Notable Drug Approvals
Review the October 2021 notable drug approvals.
Doctors Report That Kidney Grown in Pig Worked in a Human
Kidney came from pig genetically engineered to grow an organ with a low risk for being rejected by the human body
Potential Safety Concern for Guillain-Barré Syndrome ID’d for Ad26.COV2.S
Based on preliminary findings for presumptive GBS, overall observed-to-expected rate ratio estimated to be 4.18 for 42-day window
Cudetaxestat Gets Orphan Drug Status for Systemic Sclerosis
Cudetaxestat is a noncompetitive, reversible inhibitor of autotaxin.
Rethymic Approved for Pediatric Congenital Athymia
Rethymic is engineered human allogeneic thymus tissue designed to reconstitute the immune system in pediatric patients with congenital athymia.
